FREMONT, CA: Oncologists aiming to deliver the most precise medicinal practice have just found a new ally in Sema4, a patient-centered health intelligence company, which has announced the release of several new digital tools and services to conduct genomic testing. The latest set of digital products caters to a comprehensive approach, which can be utilized throughout a patient’s journey, assessing risks to cancer analysis and monitoring in remission.
The new genomic profiling solution, when made available for oncology contains the whole-exome sequencing and transcriptome sequencing. It is based on 250x tumor coverage and 100x normal coverage across all genes, with 100 million RNA reads, these services impart clinically actionable data about a wide range of genomic variants, gene fusion, alternate splicing, tumor mutational burden, and microsatellite instability. The services are majorly designed for use in FFPE, bone marrow, saliva, and blood samples analysis.
The new digital tools are built on Centrellis, Sema4’s health intelligence platform and are currently put to use for research purposes only. It includes:
• Patient journey–provision of interactive timeline visualization of the health journey of the patient, holistic diagnosis, profiling, and treatments.
• Building legions–the capacity to define a group of patients respectively, in a parameter specific care such as stage, histology, and treatments to better understand the patterns, identify appropriate clinical trials, and conduct data-driven decisions about the patient.
Clinicians at the Mount Sinai health system, along with Sema4, have co-developed the digital tools for specific applications in oncology. The team at Sema4 comprises experts in data mining, analysis, predictive modeling, and machine learning, giving it a unique edge in the generation of information in methods that will provide oncologists an added insight in the battle against cancer, especially when teamed up with advanced genomic profiling.